Sein métastatique RH+
SAFIR PI3K
A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer
Paris, Saint-Cloud
Appareil Digestif
REGIRI (PRODIGE 58)
A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas
Paris, Saint-Cloud